Call it a week of second chances. Multiple biotechs breathed new life into drugs sorely in need of it. Sage Therapeutics proved a drug that had failed a trial a rare form of epilepsy could be the first ever approved therapy for postpartum depression. Otonomy, reviving a hearing loss drug thought to be on the … Continue reading “Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi”
Category: Raleigh-Durham
What Sean Parker Shares with Einstein and the Labradoodle’s Inventor
Sean Parker, Facebook’s first president, just joined a group that’s a favorite topic of history listicles: He’s an innovator who has become abashed by the breakthrough he helped to create. Parker, in an interview with Axios on Wednesday, said Facebook’s founders consciously exploited “a vulnerability in human psychology,” by luring users into an addictive engagement … Continue reading “What Sean Parker Shares with Einstein and the Labradoodle’s Inventor”
Microsoft’s Strategy for Finding What’s Next in Healthcare A.I.
[Updated 11/10/17, 10:25 a.m. See below.] Microsoft is applying the same model it used to launch its quantum computing and chatbot efforts to innovation in healthcare, signaling the company’s ambition and optimism about the transformative potential of artificial intelligence technologies in this enormous endeavor. Peter Lee is the Microsoft Research executive in charge of the … Continue reading “Microsoft’s Strategy for Finding What’s Next in Healthcare A.I.”
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up
Exonics Therapeutics, one of the players in an emerging race to use gene therapy or gene editing techniques to treat Duchenne muscular dystrophy, has just landed a big round of funding to take its first treatment into clinical testing. The Cambridge, MA, company, seeded last year by a subsidiary of the nonprofit group CureDuchenne, will … Continue reading “With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up”
Is Your Company Independent or Co-Dependent?
Steve Jobs was once famously quoted stating, “the secret of my success is that we have gone to exceptional lengths to hire the best people in the world.” Employees are a critical part of any company’s backbone, no matter the size or industry of the business. They are the driving force that executes the company … Continue reading “Is Your Company Independent or Co-Dependent?”
$1B For Nothing? Valeant Sells Sex Drug to Sprout Backers for a Pittance
Two years after Sprout Pharmaceuticals sold itself, and its sex drive-boosting drug for women, to Valeant Pharmaceuticals in a $1 billion deal, the small company’s former owners are set to reacquire the drug for a fraction of the price. Valeant (NYSE: [[ticker:VRX]]) announced Monday an agreement to sell Sprout back to its some of its … Continue reading “$1B For Nothing? Valeant Sells Sex Drug to Sprout Backers for a Pittance”
AgTech Accelerator Brings Biopharma Models to Ag Investing Strategy
For many early-stage companies, raising money is the hard part. But after raising $10 million last spring, Boragen ran into another obstacle common to agtech startups: There are few greenhouses available for companies to run their tests. John Dombrosky, CEO of the Research Triangle Park, NC, company checked with universities and agricultural companies and found, … Continue reading “AgTech Accelerator Brings Biopharma Models to Ag Investing Strategy”
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More
The rising death toll from opioids has prompted policymakers to try various ways to take on the problem. President Trump’s opioid commission released its final report this week, calling for expansion of drug courts, better physician training, and penalties for insurers that don’t cover treatment. But the commission did not say how much its recommendations … Continue reading “Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More”
Congress Urges Tech Firms to Control Content—But With Qualms
At Congressional hearings this week on Russia’s use of social media to interfere with the 2016 U.S. election, lawmakers pressed Facebook, Twitter, and Google to take exhaustive measures to stop the same thing from happening again. Lawmakers urged the companies to scour their networks to root out foreign advertisers, trolls, and bots; to eliminate messages … Continue reading “Congress Urges Tech Firms to Control Content—But With Qualms”
Few Opioid Alternatives In Sight as Crisis Gains Political Attention
As opioid-related deaths skyrocket across the U.S., momentum to combat the epidemic has been mounting in Washington. But the crisis has also highlighted a glaring problem that no amount of politics or policymaking will solve soon: The lack of non-addictive pain medicines. “What is disappointing over the last half-century is that we haven’t really created … Continue reading “Few Opioid Alternatives In Sight as Crisis Gains Political Attention”
ASH Sneak Peeks: Novartis, Juno Update CAR-T Lymphoma Competition
[Corrected, 11/1/17, 5:20 p.m. ET. See below.] The annual American Society of Hematology meeting is next month. But previews of the big data presentations are out today, yielding more insight into what promises to be the first major competition in CAR-T cell therapy: Treatments for people with non-Hodgkin lymphoma (NHL) who have run out of … Continue reading “ASH Sneak Peeks: Novartis, Juno Update CAR-T Lymphoma Competition”
As Facebook Fights Fake News, LeCun Sees Bigger Role for A.I.
As top lawyers from Facebook, Google, and Twitter testify on Capitol Hill this week about Russians using their platforms to interfere in the 2016 U.S. presidential election, it’s becoming clearer that the fight against the spread of fake news won’t be won by humans alone. That’s according to Yann LeCun, a machine learning expert and … Continue reading “As Facebook Fights Fake News, LeCun Sees Bigger Role for A.I.”
As Russians Hacked U.S. Election, Did Big Tech Firms Break Any Laws?
News is constantly streaming out these days about the role of Facebook, Twitter, and Google in the 2016 presidential election; most disturbing to the public is the apparent use of social media, search, and video channels by Russian operatives seeking to influence U.S. voters. Critical lawmakers have blasted the big tech companies for failing to … Continue reading “As Russians Hacked U.S. Election, Did Big Tech Firms Break Any Laws?”
Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More
The White House and the FDA turned the spotlight on the nation’s opioid crisis. Blockbuster drugs from Alexion and Tesaro gained expanded approvals, but bad earnings news from Celgene and Biogen brought stocks down. Academics in the U.S. and China made progress with the gene editing technology CRISPR. And as the week’s biggest biotech deal … Continue reading “Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More”
As Drugs Fail, Some Researchers Urge a Return to Alzheimer’s Roots
As the quest to find treatments for Alzheimer’s disease keeps crashing against rocks, a group of researchers in the field want their peers to pay more attention to the part of the brain where Alzheimer’s disease first wreaks havoc. A new paper from the researchers, published this month in the journal Alzheimer’s & Dementia, is … Continue reading “As Drugs Fail, Some Researchers Urge a Return to Alzheimer’s Roots”
Cord Cutting: How to Get High-Speed Internet Without Cable, 2017 Edition
Hey folks. If you’re thinking about breaking away from the cable monopolies and getting your data, music, and video in other ways, congratulations, I’m with you. I cut the cord back in 2009, and now millions of people are doing the same every year. With the growing interest in cord-cutting, you’d think it would be … Continue reading “Cord Cutting: How to Get High-Speed Internet Without Cable, 2017 Edition”
Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal
Kite Pharma wasn’t expecting a regulatory decision for its non-Hodgkin lymphoma treatment until November, but this week, the company got the FDA’s O.K. The approval of axicabtagene ciloleucel (Yescarta) marks the second time in the two months that the FDA has given the nod to a CAR-T therapy, a treatment made from a patient’s own … Continue reading “Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal”
Level Playing Field? How Big Company Dominance May Hinder Innovation
The conventional wisdom about Silicon Valley is that it’s a playground for the underdogs, a fertile ground for young entrepreneurs building startups that are going to “change the world.” Instead, the Bay Area—while, yes, still home to thirsty young entrepreneurs—is increasingly the stomping grounds of a few major tech companies that have come to dominate … Continue reading “Level Playing Field? How Big Company Dominance May Hinder Innovation”
With Pitches for HQ2 Made, Cities Wait on Amazon’s 2018 Decision
From Portland to Pittsburgh, it’s likely that every city in the U.S. with more than 1 million people has made its case to Amazon to locate the company’s second headquarters there. At least, hopefully they have already, because today—if you haven’t heard—was the deadline to apply. Amazon sent North America into a frenzy after announcing … Continue reading “With Pitches for HQ2 Made, Cities Wait on Amazon’s 2018 Decision”
Lab Focused on Human-Centered Design Moves to Put San Diego on Map
For Michèle Morris, the big question hanging over organizers as they laid the groundwork last year for the first Design Forward Summit was whether the innovation community in San Diego understood the value of design. “We didn’t know who was going to show up—and 600 people showed up,” said Morris, who is associate director of … Continue reading “Lab Focused on Human-Centered Design Moves to Put San Diego on Map”
Kite Nabs First Adult CAR-T Approval With Notable Uptick Of Cures
For the second time in two months, remarkable recoveries from desperate cases of cancer have led to early approval of a cutting-edge therapy called CAR-T, which is made from a patient’s own genetically engineered cells. More than a month before the decision was due, the FDA has given the nod to axicabtagene ciloleucel, now branded … Continue reading “Kite Nabs First Adult CAR-T Approval With Notable Uptick Of Cures”
After Trump Sounds Off, Senate Has Adult Conversation on Drug Prices
In advance of an anticipated Senate hearing on drug prices, President Donald Trump once again denounced drug companies as “getting away with murder.” The first time he did so, using the same phrase just before his inauguration, the markets shuddered. He also said at the time that “we’re going to start bidding,” a reference to … Continue reading “After Trump Sounds Off, Senate Has Adult Conversation on Drug Prices”
After FDA Nod, TransEnterix Preps to Bring Surgical Robot to Market
TransEnterix now has regulatory clearance to bring its surgical robot to the market, but don’t expect to see surgeries performed with the technology in U.S. hospitals for at least a year, perhaps longer. Hospitals need four to six quarters to work through purchasing decisions for new capital equipment, says CEO Todd Pope. In the meantime, … Continue reading “After FDA Nod, TransEnterix Preps to Bring Surgical Robot to Market”
Gemini Reels In $42M to Target Root Causes of Age-Related Blindness
One of the biggest risk factors for vision loss is age. As people grow old, the central part of the retina can become damaged, leading patients to lose the central part of their vision in a condition called age-related macular degeneration (AMD). In recent years, scientists have found genetic factors associated with the eye damage … Continue reading “Gemini Reels In $42M to Target Root Causes of Age-Related Blindness”
Vinod Khosla on A.I., Health, and the Future of Working (or Not)
Entrepreneur-turned-venture capitalist Vinod Khosla made big headlines almost six years ago when he wrote a blog post called “Do We Need Doctors or Algorithms?” In it, he said medicine needed to be reinvented and he predicted a new era in which artificial intelligence might replace most of the functions that doctors do now—and do it … Continue reading “Vinod Khosla on A.I., Health, and the Future of Working (or Not)”
Bio Roundup: Light For Spark, California Drug Law, IPO Queue & More
In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through several towns across the state and, as of this writing, have barely been contained. With our minds on friends and loved ones affected by … Continue reading “Bio Roundup: Light For Spark, California Drug Law, IPO Queue & More”
Android Founder on VR, Voice & the Future of Human-Machine Collaboration
Within 20 years, computer keyboards will be relegated to the technology dustbin, says Android co-founder Rich Miner. Miner helped shape the smartphone era with Android, a mobile operating system startup that Google acquired in 2005. Android software now powers over 2 billion devices. On Tuesday, Miner spoke at a mobile software developer conference in Boston … Continue reading “Android Founder on VR, Voice & the Future of Human-Machine Collaboration”
FDA To Advisors: What If One-Time Gene Therapy Needs Extra Doses?
In the run-up to a key vote on an experimental gene therapy, the FDA raised no major flags about the drug’s track record but said its long-term effect remains an open question. That question should receive a thorough airing Thursday, when a meeting of FDA outside advisors will weigh a recommendation of the one-shot gene … Continue reading “FDA To Advisors: What If One-Time Gene Therapy Needs Extra Doses?”
Black Fellowship Students Headed From HBCUs to VC Boardrooms
In mid-October, eleven college students will be flying to California for an opportunity that would be the envy of any Ivy League MBA candidate—they’ll meet the venture capital firm partners who will personally mentor them throughout the school year. The students—all but one are undergraduates—come from campuses in Prairie View, Texas; Tallahassee, Florida; and Nashville, … Continue reading “Black Fellowship Students Headed From HBCUs to VC Boardrooms”
VC Funding Surges in Fewer Deals in Third Quarter, and Top 10 Deals
[Updated 10/11/17, 12:25 am. See below.] “More dollars, fewer deals” has been a prevailing trend in venture funding over the past couple of years, and it was evident again in the three months that ended September 30, according to the latest Venture Monitor report. Venture firms invested $21.5 billion in 1,699 startups nationwide during the … Continue reading “VC Funding Surges in Fewer Deals in Third Quarter, and Top 10 Deals”
Blockchain, Banks & the New Web: Q&A With Ethereum Co-founder Lubin
Ethereum co-founder Joe Lubin is calm and soft-spoken when he shares his vision of how blockchain technology and digital currencies could transform the Internet, the global economy, and many aspects of our daily lives. But what he’s talking about could become a raging tempest, and it’s worth paying attention to—especially given the vast sums of … Continue reading “Blockchain, Banks & the New Web: Q&A With Ethereum Co-founder Lubin”
Steve Case’s Rise of the Rest Shines Spotlight on Emerging Tech Hubs
Steve Case, venture capitalist, author, and co-founder of AOL, is preparing to hit the road this week on his sixth Rise of the Rest tour, where he travels to emerging innovation hubs in search of investment-worthy tech startups and to highlight the growth happening outside of places like Silicon Valley and Boston. In the years … Continue reading “Steve Case’s Rise of the Rest Shines Spotlight on Emerging Tech Hubs”
Ag Secretary Perdue Hears Startups Call for More Research Support
U.S. Secretary of Agriculture Sonny Perdue’s visit to North Carolina this week put him on stage among entrepreneurs and academics that his office chose for the occasion, and they used the opportunity to bend his ear. Joy Parr Drach, a farmer who is also CEO of Advanced Animal Diagnostics, told him about the challenges facing … Continue reading “Ag Secretary Perdue Hears Startups Call for More Research Support”
Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More
The 2017 Nobel Prizes with a biomedical bent were announced this week. Three researchers shared the physiology and medicine prize for their work shining light on the circadian rhythms that govern the wake-and-sleep cycles of all organisms. That basic research is working its way into applications such as drugs that help regulate our body clocks. … Continue reading “Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More”
AltspaceVR Finds New Home in Microsoft’s Mixed Reality Ecosystem
AltspaceVR, one of the forerunners of shared social experiences in virtual reality spaces, has been saved from extinction by Microsoft, which announced Tuesday that it is acquiring the four-year-old company. The Redwood City, CA-based startup had sounded its own death knell on July 28, announcing that it planned to shut down Aug. 3 due to the … Continue reading “AltspaceVR Finds New Home in Microsoft’s Mixed Reality Ecosystem”
Celebrating Boston Life Sciences: Xconomy Awards Gala Slideshow
We at Xconomy were thrilled to see such a great turnout at our first-ever Awards Gala—350 people from the Boston life sciences community filled a Hynes Convention Center ballroom. As Bob Buderi, our founder and editor-in-chief, said in his opening remarks on September 26 before a sold-out crowd: We clearly struck a chord. Top scientists, … Continue reading “Celebrating Boston Life Sciences: Xconomy Awards Gala Slideshow”
Twitter Joins Facebook in Political Hot Seat Over Election Hacking
Ordinarily, Twitter’s announcement that some of its users can now send tweets twice as long as its signature 140-character limit, and that this freedom could be broadened to others, would have been the company’s top news of the week. But instead, Twitter, like Facebook before it, is under the national microscope as government investigations of … Continue reading “Twitter Joins Facebook in Political Hot Seat Over Election Hacking”
Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More
After drug pricing, count drug shortages among the hot button issues sparking patient ire. Last year, the FDA says, 23 drug shortages were reported, down from 26 the previous year (and 251 in 2011). But Hurricane Maria’s direct strike on Puerto Rico might put the progress made on reducing shortages to the test. The Pharmaceutical … Continue reading “Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More”
A4L Lands $25M for Imaging Tech that Reads Heart’s Electric Signals
Electricity regulates the beats of a healthy human heart, telling its chambers when to contract. Though the role of electrical signals in heartbeats is well understood, Analytics 4 Life says they can offer much more. The startup has closed $25 million in financing to test a medical device meant to read the heart’s electrical activity … Continue reading “A4L Lands $25M for Imaging Tech that Reads Heart’s Electric Signals”
Google, Apple Offer Salvation from the Horrors of Autoplay
Tech giants are under a lot of pressure these days to make the world a better place—to ferret out Russian hackers trying to fix elections; to combat gender bias in hiring; to stamp out sexual harassment; and to lend their voices to the protests over President Trump’s immigration policies. Despite efforts they’ve made on these … Continue reading “Google, Apple Offer Salvation from the Horrors of Autoplay”
The Winners of the 2017 Xconomy Awards Are…
We are excited to announce the recipients of the first-ever Xconomy Awards. Big Idea Bridge Project The Bridge Project was hatched by MIT’s Koch Institute for Integrative Cancer Research in Cambridge and the Dana-Farber/Harvard Cancer Center in Boston to fund collaborative research between cancer researchers from MIT and Harvard-affiliated hospitals and schools. Its aim is … Continue reading “The Winners of the 2017 Xconomy Awards Are…”
Trump Orders Up $200M a Year for STEM, Coding Education
President Donald Trump, who has had a rocky relationship with tech companies during his short administration so far, announced an education initiative Monday that apparently met with their approval. In a White House ceremony, Trump directed his education secretary to allocate at least $200 million a year to fund student access to coursework in science, … Continue reading “Trump Orders Up $200M a Year for STEM, Coding Education”
San Antonio Spends $200,000 to Get New Biotech Pelican Therapeutics
San Antonio — [Updated 9/27/17, 12:02 p.m. See below.] Pelican Therapeutics, a biotech startup recently re-acquired by the company that founded it, is moving to San Antonio and receiving about $200,000 from the city’s government to do so. The San Antonio City Council approved a plan last week to give the grant to Pelican as long … Continue reading “San Antonio Spends $200,000 to Get New Biotech Pelican Therapeutics”
Xconomy Q&A: Todd Schulte of Tech Immigration Advocacy Org FWD.us
[Updated 9/25/17, 1:55 p.m. Clarified 9/27/17, 10:01 a.m. See below.] Immigration policy has always been important to the tech industry, but this year is different. Under a steady barrage of nationalist, anti-immigrant policies promulgated by the Trump administration, the tech industry has been forced to respond like never before, in the halls of Congress, the … Continue reading “Xconomy Q&A: Todd Schulte of Tech Immigration Advocacy Org FWD.us”
Low-Hanging Fruit Gone, Ag & Food Tech Investors Pay More for Deals
[Updated 9/25/17, 5:18 pm. See below.] Food delivery startups are catching on with more consumers, and that demand is whetting investor appetites. The $400 million that grocery delivery startup Instacart raised in March marked the largest deal for a U.S. food technology company in the first half of the year, according to new data from … Continue reading “Low-Hanging Fruit Gone, Ag & Food Tech Investors Pay More for Deals”
Epic’s App Orchard Gains Traction with Hospitals, Third Parties
In February, Epic Systems formally introduced App Orchard, a program aimed at helping other healthcare software companies integrate their digital products with Epic’s tools for managing patient records. Hundreds of health systems around the world already use Verona, WI-based Epic’s software to document patient information. Doctors, nurses, and other healthcare workers can use the software … Continue reading “Epic’s App Orchard Gains Traction with Hospitals, Third Parties”
Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More
It’s been a year of biomedical milestones in the U.S., including the first approval of a CAR-T cellular immunotherapy, the first smartphone app to treat substance abuse, and the first approval of a cancer drug based on genetic signature instead of the tumor’s organ of origin. Add to the list the first successful Phase 3 … Continue reading “Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More”
Nathan Myhrvold: The Full Xconomy Voices Interview
Episode 3 of our new podcast, Xconomy Voices, features a conversation about nuclear power with Nathan Myhrvold, the founder and CEO of Intellectual Ventures. The former Microsoft chief technology officer is now vice chairman of TerraPower, a Bellevue, WA-based spinout of Intellectual Ventures that aims to revive commercial nuclear energy. The company is researching next-generation … Continue reading “Nathan Myhrvold: The Full Xconomy Voices Interview”
Xconomy Voices, Episode 3: Nathan Myhrvold and TerraPower
We’re pleased to bring you the third episode of Xconomy Voices, our new podcast featuring conversations with entrepreneurs, innovators, and investors from Xconomy’s home cities and regions. This week our guest is Nathan Myhrvold, the former Microsoft chief technology officer who, since 2000, has headed Intellectual Ventures, a Bellevue, WA-based firm that buys, develops, and … Continue reading “Xconomy Voices, Episode 3: Nathan Myhrvold and TerraPower”
NVCA Sues Trump Administration for Delaying “Startup Visa” Program
Add another item to the list of tech industry beefs with the new crew in the White House. An organization representing venture capital firms filed a federal suit in Washington, DC, on Tuesday accusing Trump Administration officials of unlawfully delaying a program that would have allowed international entrepreneurs to work at companies they founded within … Continue reading “NVCA Sues Trump Administration for Delaying “Startup Visa” Program”